We use cookies to improve your experience on this site. By viewing our pages, you give us consent to use cookies. Find out more.

Don’t invest unless you’re prepared to lose all the money you invest. NextFin promotes high - risk investments and you are unlikely to be protected if something goes wrong.
Take 2 minutes to learn more.

Equity Crowdfunding Pitches

Showing results
Ablatus Therapeutics is a MedTech company developing a one-of-a-kind tissue ablation platform known as Bimodal Electric Tissue Ablation (BETA). This technology has been designed to overcome the limitations of existing products by offering ablation solutions in oncology (tumours) as well as non-oncology targets. With the proceeds, the company will finish the final elements of engineering of the generator and probe. It will also deliver formal safety test data that is a prerequisite for subsequent clinical trials.
days to go: Expired investment: Withheld
MedicSpot is a healthcare company that is aiming to revolutionise healthcare delivery by combining the advantages of online and offline care. The company provides patients at designated hospitals with diagnostic tools like a stethoscope, oximeter, blood pressure monitor and thermometer which, in turn, is connected to the MedicSpot network. Onboard General Physicians (GPs) engage in live sessions with patients, guide them on how to use the tools, and perform a variety of diagnoses like listening to a patient’s heart and lungs, looking down their throat and into their ears, taking their blood pressure and oxygen readings, and measuring their body temperature. The company is also expanding into another subsidiary, Arc Health, which it claims will perform the aforementioned tasks with more efficiency and accuracy. The company will use the investment to increase the number of Medicspot clinics to 1,000, gain further NHS market share, launch a corporate business model and allow international pilots to take place.

Pitch Rated

52%

Insufficient Data

rating powered by

CROWD RATING™

days to go: Expired investment: £1,048,396
MGB Biopharma is tackling the worldwide threat of antimicrobial resistance.   The company is in the process of clinical study and designing a new class of antibiotic.  They are looking for investment to start phase 2 of the study with 70% being supported by a grant.
days to go: Expired investment: £1,309,621
During their stay in hospital, around 7-10% of patients attract unexpected infections. In some cases, this is caused by unclean complex surgical tools. Aspetium have developed ultrasonic washers (dubbed "uSonic") to thoroughly decontaminate expensive surgical instruments, which can be safely reused to potentially prevent easily avoidable infections.
days to go: Expired investment: £151,167
FreeHand is a robotic surgical camera controller that aims to make surgeries precise and safer. The company cites data arguing that over 15 million keyhole surgeries are performed annually in which an additional clinician is mostly required to manually hold the camera the surgeon uses to see the operating field. The company asserts that this is not the most optimal way. FreeHand's robotic camera controller aims to solve this issue by providing steady images and precise control, saving time, and improving outcomes. The company has regulatory clearance for sale in the EU, US, and Japan. FreeHand points out that surgical robotics is one of the fastest-growing segments in Medical Technology, projected to reach $91.5 billion by 2025. It aims to become a contender in this segment. FreeHand claims that surgeons have successfully used its robotic controller in more than 15,000 procedures. The company will use the investment to expand the distributor base in Europe, Asia and Latin America, targeting over 12 million procedures annually.
days to go: Expired investment: £1,003,350
Pioneering medical device company with patented technologies in the "key hole" surgery market 
days to go: Expired investment: £600,083
OvuSense has been designed for women that struggle to conceive, actively predicting fertility patterns.  The OvuSense system has two parts a smartphone app and a medical grade vaginal sensor. OvuSense works for all women. The product gives a 24 hour prediction within your cycle.
days to go: Expired investment: £100,000
Providing convenient and affordable healthcare to patients either at home or their workplace. Practitioners can visit patients and offer a range of medical treatments including vaccinations, testing, physiotherapy and primary care. Qured have been highly successful in London and are growing at an alarming rate, ready to help the whole of the UK.
days to go: Expired investment: £763,160
OVD Development Ltd. owns IP rights for fluorescent products used for ophthalmic surgery, which is basically a new approach to viscoelastic medium (OVD). The goal of OVD Development Ltd. is to complete the CE marking process. Till 2017, it estimates to be worth $560 million with an expected 11.6% average annual growth in the global market.
days to go: Expired investment: £82,300
An end-to-end digital platform providing aesthetic medical treatment in a market valued at almost £76bn. NowMe work closely with customers throughout the process by discussing the treatment they desire, selecting an appropriate medical practitioner from a UK Clinic and offering available finance solutions. The company is raising funds to refine their product and secure IP, as well as cover working capital requirements. The firm plan to launch in 2018 and by 2025 achieve international leadership.
days to go: Expired investment: £172,790
  • Internet Business Awards Category Award Winner 2015
  • Hertfordshire Business Awards Finalist 2014

As seen in:

  • The Guardian
  • Financial Times
  • Yahoo! Finance
  • The Times
  • The Daily Telegraph